

Ref: SPL/CORP-SEC/2026-27/BSE/30

Dated:05.05.2026

To,
Bombay Stock Exchange Ltd,
Phirojshah Jeejobhoy Towers,
25th Floor, Dalal Street,
Mumbai 400 001

Manager-Department of Corporate affairs

Sir,

Sub: Outcome of the Board Meeting held on 05TH May 2026 with Scrip Code 524703.

Ref: Regulations 30 and 33 of SEBI (Listing Obligations & Disclosure Requirements) Regulations. 2015

A Meeting of the Board of Directors of the Company duly convened on Tuesday, 05th May 2026 at 03:00 p.m. and concluded at 5.50 p.m. discussed the following business: -

1. Standalone Audited Financial Results for the quarter and year ended 31st March 2026 reviewed by Audit Committee and placed before the Board of Directors in their meeting held today. The same is approved and taken on record by the Board.

A copy of the Standalone Audited Financial Results for the quarter and year ended 31st March, 2026 along with the Auditor's Report and Declaration pursuant to the Regulation 33 (3) (d) of SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015 are enclosed herewith as Annexure I.

The Standalone Audited Financial Results for the quarter and year ended 31st March, 2026 and the Auditor's Report will also available on the website of the company at www.sandu.in.

2. Recommendation on final dividend :

The Board has recommended final dividend of Rs. 1 per equity share (i.e 10% on paid up Share Capital of the Company) having face value of Rs.10/- each for the financial year ended 31st March 2026, subject to the approval of the shareholders at the ensuing Annual General Meeting. Record date/ Book Closure and Dividend Payment date will be informed in the due course of time.

3. Appointment of Cost Auditor:

- a. Board of Directors based on the recommendation received from the Audit Committee have considered and recommended appointment of M/s Shekhar Joshi & Co, (Registration No. 100448) Cost Accountant as the Cost Auditor of the Company for the financial year 2026-27.
- b. The details as required under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated 11th November 2024, regarding item no 3 is enclosed as Annexure - II.

4. On Recommendation of Audit Committee ,Board of Director has Considered and Appointed M/S Akhil Pai & Co, as the internal Auditor of Goa Plant Operations and M/S Uday & Uday Associates Chartered Accountant as The Internal Auditor for Mumbai for The Financial



SANDU PHARMACEUTICALS LIMITED

CIN:L24233GA1985PLC001587

Regd. Office: Plot Nos. 25, 26, 29 & 30, Pilerne Industrial Estate, Marra, Saligao, Bardez, Goa 403511.

Tel: +91 832 2407474 / 6715000, E-mail: sandupharma@sandu.in, Website: www.sandu.in

Year 2026-27. The detailed disclosures as required under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated 11th November 2024, is enclosed as Annexure III.

5. Took note of Statement of Utilizations and Deviations as per Regulation 32 of SEBI (LODR) Regulation 2015 for the Quarter ended 31st March 2026.

FOR SANDU PHARMACEUTICALS LIMITED.



Pratika Mhambray
Company Secretary
ACS :36512



AN ISO 9001:2015 CERTIFIED ORGANISATION
Corporate Office: P. B. No. 17201, Sandu Nagar, D. K. Sandu Marg, Chembur, Mumbai – 400 071.
Tel.: +91 22 2528 4402 / 3306, E-mail: info@sandu.in



Annexure II

Disclosure of information pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Circular No. SEBI/HO /CFD/PoDZ/CIR/P/0155 dated November 11, 2024:

Sr No	Particulars	Details
1.	Reason for change viz. appointment, resignation, removal, death or Otherwise Completion of their terms	Reappointment
2.	Date of appointment/ Cessation and terms of appointment;	Date of Reappointment 05.05.2026 Term of appointment: Financial Year 2026-27
3.	Brief Profile (in case of appointment);	<p>M/s Shekhar Joshi & Co is a firm of Cost Accountants practicing as Cost Accountant (Registration No. 100448).CMA Shekhar Joshi ia M.Com, LL.B, FCMA, M.B.A. with 35 plus years of experience. He is Visiting Faculty at The ICFAI Business School, Sterling Institute of Management, The Atharva Institute of Management Studies, Finplan Institute and Institute of Cost Accountants of India</p> <p>Areas of Specialization Cost Audit• Management Consultancy• Statutory Compliances• Business Valuation for Banking and Take Over• Assisting Mergers and Acquisitions• Due Diligence• Project Appraisal and Evaluation• Internal and MIS systems• Stock Audits• Product Costing• Market Profitability Analysis.</p> <p>Projects Handled Cost Audit and Cost Compliances• Implementation of Costing Systems• Due Diligence• Feasibility study of Merger• Corporate Valuations• MIS Implementation• Costing MIS and Routine Assistance• Budgets and Follow ups</p>
4.	Disclosure of relationships between directors. (in case of Appointment)	M/s Shekhar Joshi & Co ,Cost Auditors is not related to any of the Directors or Key Managerial Personnel or Promoters and Promoter group of the Company

Annexure III

Disclosure of information pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Circular No. SEBI/HO /CFD/PoDZ/CIR/P/0155 dated November 11, 2024:

Sr No	Details of events that need to be provided	Information of such event(s)	
		Reappointment	
		1. M/S Akhil Pai & Co	2. M/S Uday & Uday Associates
<u>1</u>	Reason for change viz. appointment, resignation, removal, death or Otherwise Completion of their terms	Considering the term of expiry of internal auditor for Goa Plant operations, CA Akhil Pai & Co is reappointed for further period of 01 year that is for the FY 2026-27 .	Considering the term of expiry of internal auditor for Mumbai, CA Akhil Pai & Co is reappointed for further period of 01 year that is for the FY 2026-27
<u>2</u>	Date of appointment/ Cessation and terms of appointment;	05.05.2026 Term:for the FY 2026-27	05.05.2026 Term:for the FY 2026-27
<u>3</u>	Brief Profile (in case of appointment);	He is Practising Chartered Account . he has conducted Tax Audits of Proprietorship Concerns, Firms and Companies, and also look into other Companies law matters, Income Tax related & GST matters.	Practicing chartered Accountant firm specialized in Companies Audit, Cooperative Sector Audit ,Nationalized Bank Audit etc.
<u>4</u>	Disclosure of relationships between directors. (in case of Appointment)	Akhil Pai & Co is not related to any of the Directors or Key Managerial Personnel or Promoters and Promoter group of the Company.	Uday & Uday Associates is not related to any of the Directors or Key Managerial Personnel or Promoters and Promoter group of the Company.

FOR SANDU PHARMACEUTICALS LIMITED.



Pratika Mhambray
Company Secretary
ACS : 36512

SANDU PHARMACEUTICALS LIMITED

Statement of Profit and Loss for the Period ended 31st March, 2026

(Rs in lakhs)

Particulars	3 Months ended	Preceding 3 Months Ended	Corresponding 3 Months ended	Year ended	Year ended
	31 st March 2026	31st December, 2025	31st March 2025	31st March 2026	31st March 2025
	Audited	Unaudited	Audited	Audited	Audited
INCOME					
Revenue From Operations	1685.34	1876.09	1406.92	6993.45	6719.24
Other income	36.51	1.37	6.94	44.44	16.75
Total income	1721.85	1877.46	1413.85	7037.89	6735.99
EXPENSES					
Cost of materials consumed	383.94	281.31	301.49	1101.18	1011.98
Purchases of Stock-in-Trade	351.54	349.94	728.92	1648.07	2318.45
Changes in inventories of finished goods, Stock-in-Trade and work-in-progress	-83.01	157.47	-452.56	407.95	-120.24
Employee benefits expense	274.28	264.65	282.74	1069.08	1092.03
Finance costs	2.56	3.35	2.63	11.21	10.33
Depreciation and amortization expense	16.49	16.58	14.81	67.70	67.06
Other expenses	701.34	718.66	501.57	2467.16	2140.80
Total expenses	1647.14	1791.96	1379.61	6772.35	6520.41
Profit/(loss) before exceptional items and tax	74.71	85.50	34.24	265.54	215.58
Exceptional items / Prior Period Adjustment			.00		.00
PROFIT/(LOSS) BEFORE TAX	74.71	85.50	34.24	265.54	215.58
Tax expense:					
Current tax	-42.13	4.89	7.41	-66.64	-58.86
Deferred tax	-16.36	7.12	(5.81)	-10.41	-1.83
Short / (Excess) Tax Provision	-11.89	.00	-	-11.89	.00
PROFIT (LOSS) FOR THE PERIOD	4.34	97.51	32.64	176.61	154.89
OTHER COMPREHENSIVE INCOME					
Items that will not be reclassified to profit or loss in Subsequent Periods :					
Remeasurement gains/(losses) on post employment defined benefit plans	8.11	.00	(12.66)	8.11	-12.66
Fair value changes of investments	74.61	19.70	21.35	74.61	82.95
Income tax relating to items that will not be reclassified to profit or loss	-16.38	-2.74	1.15	-16.38	-5.71
TOTAL OTHER COMPREHENSIVE INCOME FOR THE PERIOD (NET OF TAX)	66.35	16.96	9.84	66.35	64.58
TOTAL COMPREHENSIVE INCOME FOR THE PERIOD (NET OF TAX)	70.68	114.47	42.48	242.95	219.47
Paid Up Equity Capital (Face Value of Rs 10/- Per share)	966.10	966.10	966.10	966.10	966.10
EARNINGS PER EQUITY SHARE					
Basic	0.04	1.01	0.34	1.83	1.60
Diluted	0.04	1.01	0.34	1.83	1.60

Place :- Mumbai
Date :- 05/05/2026



For Sandu Pharmaceuticals Ltd

Umesh Sandu
Managing Director
DIN :- 01132141

SANDU PHARMACEUTICALS LIMITED

Balance Sheet as at 31st, March, 2026

(Rs in lakhs)

PARTICULARS	As at 31st March, 2026	As at 31st March, 2025
	Amount (')	Amount (')
ASSETS		
Non-current assets		
Property, Plant and Equipment	868.47	846.56
Right of use assets	942.13	965.62
Capital Work in Progress	6.41	-
Other Intangible Assets	1.86	2.39
Financial Assets		
Investments	1229.80	1122.42
Other Financial Asset	3.08	5.00
Other Non-Current Assets	3.24	-
	3054.99	2941.98
Current assets		
Inventories	1047.13	1414.86
Financial Assets		
Trade receivables	541.09	475.73
Cash and cash equivalents	590.77	130.39
Bank balances other than 9 (a) above	94.82	134.91
Other current assets	258.11	473.99
	2531.94	2629.88
	5586.93	5571.87
EQUITY AND LIABILITIES		
Equity		
Equity Share capital	966.10	966.10
Other Equity	3401.23	3235.62
	4367.33	4201.72
Non-current liabilities		
Financial Liabilities		
Finance Lease obligations	30.95	41.93
Deferred tax liabilities (Net)	146.44	119.64
	177.39	161.57
Current liabilities		
Financial Liabilities		
Finance Lease obligations	10.98	5.82
Trade payables Due to :		
Micro and Small Enterprises	61.72	32.72
Other than Micro and Small Enterprises	385.03	416.00
Other Financial Liabilities	31.27	25.00
Other current liabilities	206.59	190.67
Provisions	346.63	538.35
	1042.21	1208.58
	5586.93	5571.87

Place :- Mumbai
Date :- 05/05/2026



For Sandu Pharmaceuticals Ltd

Umesh Sandu
Managing Director
DIN :- 01132141

SANDU PHARMACEUTICALS LIMITED
Statement of Cash Flow for the year ended 31st Mar, 2026

(Rs in lakhs)

Particulars	Year ended 31st Mar, 2026		Year ended 31st March, 2025	
	Amount (₹)	Amount (₹)	Amount (₹)	Amount (₹)
A. Cash flow from operating activities				
Net Profit / (Loss) before extraordinary items and tax		265.54		215.58
Adjustments for:				
Depreciation and amortisation expenses	67.70		67.06	
Finance costs	11.21		10.33	
Interest income	-5.89		(11.05)	
Other Income	.00		-	
Loss on Sale of Investment in Subsidiary Sandu Phytoceuticals P Ltd	.00		0.33	
Allowance for doubtful debts / expected credit losses - trade receivable	48.60		16.11	
Equity Instruments through Other Comprehensive Income	.00		-	
Re-measurement gains/losses on employee defined benefit plans	8.11		(12.66)	
		129.72		70.12
Operating profit / (loss) before changes in operating assets & liabilities		395.26		285.70
Changes in operating assets				
(increase) / decrease in inventories	367.73		(189.80)	
(increase) / decrease in Trade receivables	-113.94		(5.02)	
(increase) / decrease in other operating assets	25.71		(17.81)	
Changes in operating liabilities				
(increase) / decrease in trade payables	-2.03		29.34	
(increase) / decrease in other operating liabilities	13.84	291.30	50.95	(132.34)
Cash Generated from operation		686.54		153
Income Tax Paid		-74.98		(58.32)
Net Cash flow from Operating activities		611.58		95.04
B. Cash flow from investing activities				
Purchases of Property, Plant and Equipment	-72.00		(93.80)	
Proceeds from Maturity of Fixed Deposits placed with Banks	70.00		191.90	
Fixed deposits placed with banks	-28.00		(130.00)	
Interest received	5.89		11.05	
Other Income	.00		0.67	
Proceed from Sale of Investment in Subsidiary Sandu Phytoceuticals P Ltd	.00		-	
Proceeds from Sales of Mutual Funds /Shares	74.61		152.23	
Purchases of Mutual fund / Shares designated as FVTOCI	-107.38		(150.00)	
Net cash flow from / (used in) investing activities (B)		-56.88		(17.96)
C. Cash flow from financing activities				
Finance lease obligations	-5.82		41.42	
Finance cost	-11.21		(10.33)	
Dividend Paid	-77.29		(77.29)	
Net cash flow from / (used in) financing activities (C)		-94.32		(46.20)
Net increase / (decrease) in Cash and cash equivalents (A+B+C)		460.38		30.84
Cash and cash equivalents at the beginning of the year		130.39		99.55
Cash and cash equivalents at the end of the year		590.77		130.39

Notes:

- The above Standalone Statement of Cash Flows has been prepared under the 'Indirect Method' as set out in Ind AS 7, 'Statement of Cash Flows'.
- For the purpose of presentation in the statement of cash flows, cash and cash equivalents includes cash on hand, other short-term highly liquid investments with original maturities of three months or less that are readily convertible to known amounts of cash and which are subject to an insignificant risk of changes in value.

Reconciliation of cash and cash equivalents with the balance sheet :

(Rs in lakhs)

Particulars	31st March, 2026	31st March, 2025
As per Balance Sheet	590.77	130.39
Balance as per statement of cash flows	590.77	130.39

Place :- Mumbai
Date :- 05/05/2026



For Sandu Pharmaceuticals Ltd

Umesh Sandu
Managing Director
DIN :- 01132141

1. The above results published in accordance with regulation 33 of the SEBI (Listing Obligation & Disclosures Requirements), 2015 .The Financials results are in accordance with the Indian Accounting Standards (IND AS) as prescribed under Section 133 of the Companies Act, 2013 read with Rule 3 of the Companies (Indian Accounting Standards) Rule, 2015 and Companies (Indian Accounting Standards) Amendment Rules, 2017.
2. The Management evaluates the performance of the company based on revenue and operating income in one segment i.e. "Ayurvedic Property Medicines". Accordingly, as per IND AS- 108. The company has only one business segment and hence segment information has not been separately disclosed.
3. The above results were reviewed and recommended by the Audit Committee and approved by the Board of Directors at the meeting held on 05/05/2026.
4. The Figures for the quarter ended 31 st March, 2026 are the balancing figures between the audited figures in respect of the full financial year and the published year to date figures up to the third quarter of the respective financial year.
5. Figures for the previous periods have been reclassified/regrouped, whenever necessary.

For Sandu Pharmaceuticals Ltd



Date: - 05/05/2026

Umesh Sandu
Managing Director
DIN no: - 01132141

Independent Auditor's Report on Quarterly and Year to date Standalone Financial Results pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015

To,

**The Board of Director of,
SANDU PHARMACEUTICALS LIMITED**

Report on the audit of the Standalone Financial Results

Opinion

We have audited the accompanying statements of standalone Financial Results of **SANDU PHARMACEUTICALS LIMITED** (“the Company”), for the quarter and year ended on March 31, 2026 (‘the statement’) being submitted by the company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015, as amended (‘the Listing Regulations”).

In our opinion and to the best of our information and according to the explanations given to us, these financial results:

- a. Are presented in accordance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 in this regard; and
- b. Gives a true and fair view in conformity with the Indian Accounting Standard 34 “Interim Financial Reporting” (Ind AS 34”) prescribed under Section 133 of the Companies Act 2013 (the “Act”) read with relevant rules issued thereunder and other accounting principles generally accepted in India of the net profit and total comprehensive income and other financial information of the Company for the quarter and year ended on March 31, 2026.

Basis for Opinion

We conducted our audit in accordance with the Standards on Auditing (SAs) specified under section 143(10) of the Companies Act, 2013(the Act). Our responsibilities under those Standards are further described in the Auditor’s Responsibilities for the Audit of the standalone financial results section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the financial results under the provisions of the Companies Act, 2013 and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Management Responsibilities for the Standalone Financial Results

These quarterly financial results as well as the year to date standalone financial results have been prepared on the basis of the Audited financial statements. The Company's Board of Directors are responsible for the preparation of these financial results that give a true and fair view of the net profit and other comprehensive income and other financial information in accordance with applicable accounting standards prescribed under Section 133 of the Act read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate 'internal financial controls that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the financial results that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the Standalone financial results, the Board of Directors are responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

The Board of Directors are also responsible for overseeing the Company's financial reporting process.

Auditor's Responsibilities for the Standalone Financial Results

Our objectives are to obtain reasonable assurance about whether the standalone financial results as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial results.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain Professional skepticism throughout the audit. We also:

- a. Identify and assess the risks of material misstatement of the Standalone financial results, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- b. Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, Under Section 143(3)(i) of the Act, we are also responsible for expressing our opinion on whether the Company have adequate financial control reference to Financial Statement in place and the operating effectiveness of such control.
- c. Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Board of Directors.

- d. Conclude on the appropriateness of the Board of Directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial results or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- e. Evaluate the overall presentation, structure and content of the Standalone financial results, including the disclosures, and whether the financial results represent the underlying transactions and events in a manner that achieves fair presentation.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.


Other Matter

- a. The Statement dealt with by this report has been prepared for the express purpose of filing with BSE Limited. This Statement is based on and should be read with the financial results of the company for the quarter and year ended March 31, 2026 on which we issued an unmodified audit opinion vide our report dated May 5, 2026.
- b. The Statement includes the results for the quarter ended March 31, 2026, being the balancing figures between audited figures in respect of the full financial year and the published year-to-date figures up to December 31, 2025 being the date of the end of the third quarter of the current financial year.

For Dileep & Prithvi

Chartered Accountants

Firm Registration Number: 122290W



Himmat Mali

(Partner)

Membership Number: 183378

UDIN: 26183378UZMCMK2744

Place: Mumbai

Date: May 5, 2026



SANDU PHARMACEUTICALS LIMITED

CIN:L24233GA1985PLC001587

Regd. Office: Plot Nos. 25, 26, 29 & 30, Pilerne Industrial Estate, Marra, Saligao, Bardez, Goa 403511.

Tel: +91 832 2407474 / 6715000, E-mail: sandupharma@sandu.in, Website: www.sandu.in

Ref: SPL/CORP-SEC/2026-27/BSE/27

Dated:05.05.2026

To,
Bombay Stock Exchange Ltd,
Phirojshah Jeejobhoy Towers,
25th Floor, Dalal Street,
Mumbai 400 001

Scrip Code: 524703

Sub: Declaration regarding Audit Report on Standalone Financial Results for the Quarter and Year ended 31st March 2026 with unmodified opinion of the Independent Auditors.

Dear Sir,

We hereby confirm and declare that the Statutory Auditors of the Company i.e M/s Dileep and Prithvi, Chartered Accountants, Mumbai (Firm No:122290W), have issued the Audit Report on Standalone and Consolidated Financial Results of the Company for the Quarter and Year ended 31st March 2026 with Unmodified opinion.

We submit this declaration as required under the provisions of the Regulation 33(3) (d) of SEBI (Listing Obligations and Disclosure Requirements) 2015 as amended and circular CIR/CFD/CMD/56/2016 May, 2016 issued by SEBI.

You are requested to take the above letter on record.

Yours Faithfully
For Sandu Pharmaceuticals Limited

Umesh B Sandu
Managing Director
DIN: 01132141



AN ISO 9001:2015 CERTIFIED ORGANISATION

Corporate Office: P. B. No. 17201, Sandu Nagar, D. K. Sandu Marg, Chembur, Mumbai – 400 071.

Tel.: +91 22 2528 4402 / 3306, E-mail: info@sandu.in





SANDU PHARMACEUTICALS LIMITED

CIN:L24233GA1985PLC001587

Regd. Office: Plot Nos. 25, 26, 29 & 30, Pilerne Industrial Estate, Marra, Saligao, Bardez, Goa 403511.

Tel: +91 832 2407474 / 6715000, E-mail: sandupharma@sandu.in, Website: www.sandu.in

Ref: Corp.Sec/BSE/2026-27/430

Dated:05.05.2026

To,
Department of Corporate
Services Bombay Stock
Exchange Limited,
Phirojshah Jeejobhoy tower,
Dalal Street, Mumbai-400001.

Sub. -: Non-Applicability of SEBI Circular dated 19th October 2023 with regard to fund raising by issue of debt securities by Large entities-Annual Disclosure

Ref. - Circular Issued by Securities and Exchange Board of India ("SEBI") bearing reference No. SEBI/HO/DDHS/DDHS-RACPOD1/P /CIR / 2023 /172 dated October 19, 2023 ("Circular")

Dear Sir,

With reference to the Securities and Exchange Board of India (SEBI) Operational Circular No. SEBI/HO/DDHS/P/CIR/2021/613 updated as on August 10, 2021 as amended from time to time, read with Latest circular no. SEBVHO/DDHS/DDHS-RACPOD1/P/CIR/2023/172 dated October 19, 2023, we would like to inform you that Sandu Pharmaceuticals Limited ("the Company") is not a Large Corporate, as per the framework/criteria specified at operational Circular so Annual Disclosure under Annexure B2 is not required to submitted by our Company.

We are enclosing herewith details in the format as prescribed in Annexure I of the aforesaid Circular for the financial year ended on 31st March, 2026.

For Sandu Pharmaceuticals Limited

Pratika Mhambray

Pratika Mhambray
Company Secretary and Compliance Officer
A:36512



AN ISO 9001:2015 CERTIFIED ORGANISATION

Corporate Office: P. B. No. 17201, Sandu Nagar, D. K. Sandu Marg, Chembur, Mumbai – 400 071.
Tel.: +91 22 2528 4402 / 3306, E-mail: info@sandu.in





SANDU PHARMACEUTICALS LIMITED

CIN:L24233GA1985PLC001587

Regd. Office: Plot Nos. 25, 26, 29 & 30, Pilerne Industrial Estate, Marra, Saligao, Bardez, Goa 403511.

Tel: +91 832 2407474 / 6715000, E-mail: sandupharma@sandu.in, Website: www.sandu.in

ANNEXURE A:

Sr No	Particulars	Details
1	Name of the Company	Sandu Pharmaceuticals Limited
2	CIN	L24233GA1985PLC001587
3	Outstanding borrowing of the Company as on 31 st March 2026	0
4	Highest Credit rating during the previous FY along with the name of Credit rating Agency	NA
5	Name of the Stock Exchange on which fine to be levied in case of shortfall in the required borrowing under the framework	NA

We confirm that we are a Not Large Corporate as per the applicability criteria given under the SEBI Operational Circular No. SEBI/HO/DDHS/P/CIR/2021/613 updated as on August 10, 2021 as amended from time to time, read with Latest circular no. SEBVHO/DDHS/DDHS-RACPOD1/P/CIR/2023/172 dated October 19, 2023.

You are requested to kindly take note of the same.

Thanking you

For Sandu Pharmaceuticals Limited

Pratika Mhambray
Company Secretary
Cont No:7208025419

Vijay Kajarekar
Chief Financial Officer
Cont No:9049919108

Dated: 05/05/2026



AN ISO 9001:2015 CERTIFIED ORGANISATION

Corporate Office: P. B. No. 17201, Sandu Nagar, D. K. Sandu Marg, Chembur, Mumbai - 400 071.

Tel.: +91 22 2528 4402 / 3306, E-mail: info@sandu.in

